What was broken
A deep-tech firm working on patient-facing health monitoring needed funding to advance product development.
What we did
CapEasy prepared the seed-fund proposal — product milestones, a utilisation plan, and multi-year financials. The application was aligned to the program’s eligibility and permitted-activity rules.
Where it landed
The firm secured a public seed-fund approval. A seed-fund approval is the incubator committee’s sanction; actual disbursement follows the program’s due-diligence and compliance milestones and is not guaranteed.
The federal program built for a health-tech device, not a drug
SBIR and STTR are congressionally mandated set-asides run across 11 participating federal agencies, each managing its own solicitations and topics under shared program rules. For a patient-facing health monitoring device, NIH is the sector-matched agency — and inside NIH, the National Institute of Biomedical Imaging and Bioengineering (NIBIB) is a sector-matched institute for this class of technology. NIBIB’s Small Business Program strongly encourages applicants to contact program staff before submitting an application, so topic fit gets checked before a budget line is written. Depending on what the device actually measures, NHLBI (cardiovascular) or another institute could equally be the right funding home — the fit conversation happens first, not after submission.
On award size: as of April 2026, SBA’s government-wide SBIR/STTR guideline sits at $323,090 for Phase I and $2,153,927 for Phase II, including modifications, with amounts above that requiring an SBA waiver. NIH does not use one number, though — each participating institute publishes its own budget guidance in the specific funding opportunity, and NIH holds an SBA waiver that lets it exceed the standard figures for approved biomedical topics. The number that matters is the one printed in the funding opportunity you are applying under, not the government-wide guideline.
What a reviewer reads in the budget file
NIH SBIR/STTR applications are built on the detailed SF424 Research & Related Budget component, not the modular budget many R01 investigators use — every cost category needs its own line-item justification: personnel, equipment, supplies, and any subcontract to a clinical site, lab or CRO. A health monitoring device with human-subjects testing carries cost lines a hardware-only SBIR never has to justify: participant compensation, IRB review fees, and — if the testing meets NIH’s definition of a clinical trial — a separate PHS Human Subjects and Clinical Trials Information form attached to the application, answered even when the human-subjects work happens at a partner site rather than the small business itself.
Indirect costs get their own scrutiny too. An applicant carrying a current negotiated indirect cost rate agreement (NICRA) from a prior federal award states it and attaches it; an applicant without one states the alternative NIH’s Grants Policy Statement allows an unrated small business to claim. Either way, the rate has to sit on the page tied to a real basis — a number that just appears, with no NICRA and no stated election behind it, is exactly what a reviewer flags before reading further.
The file that keeps the money flowing after approval
The milestone-and-utilisation-plan discipline that carried the engagement through committee is the same discipline NIH expects after the award, just filed through different forms. An annual Research Performance Progress Report (RPPR), submitted through eRA Commons, narrates progress against the milestones stated in the original application. Separately, a Federal Financial Report (SF-425) reconciles actual spend against the awarded budget, filed through the Payment Management System on the schedule stated in the Notice of Award, with a closing FFR due at the end of the award. Two filings, two purposes — one tells the science story, the other reconciles the dollars — and NIH expects both, on their own schedules.
If the device testing meets NIH’s definition of a clinical trial — a category that reaches further than the FDA’s, pulling in even small feasibility studies of device products — registration and results reporting at ClinicalTrials.gov becomes part of the award’s compliance record, not an optional extra. CapEasy’s part in a file like this is the cost-tracking build: ledgers reconciled to a state that can produce the SF-425 on schedule, a milestone-to-cost mapping that survives an RPPR review, and the documentation trail behind every budget line. The clinical-trial designation itself, the eligibility determination, and anything filed on the SF424, RPPR or SF-425 forms run through your grant administrator and the partner CPA firms we work with across 15 US states.
What to take from it
- For a patient-facing health monitoring device, NIBIB is a sector-matched NIH SBIR/STTR institute — contact program staff before you draft the budget, not after.
- NIH SBIR/STTR runs on the detailed SF424 R&R Budget, not the modular form — every cost category needs its own line-item justification.
- If device testing meets NIH’s definition of a clinical trial — which reaches even small feasibility studies — a separate Human Subjects and Clinical Trials Information form and ClinicalTrials.gov registration join the file.
- State your indirect-cost basis on the page: a carried-over NICRA or the alternative NIH’s Grants Policy Statement allows an unrated small business to claim. An unstated rate gets flagged before the science does.
- Approval is not the finish line: an annual RPPR narrates progress against milestones and a separate SF-425 reconciles spend against budget, each on its own schedule.